Cancer pain
Conditions
Interventions
Genetic Locus Testing:NO
Experimental Group:After the correlation analysis of the first 100 patients is completed and preliminary results are obtained, individualized treatment will be implemented for subsequent patients in t
Control Group:The control group received standard oxycodone treatment, with doses adjusted according to clinical guidelines or the experience of doctors/pharmacists, without reference to genotype.
Sponsors
Putuo District Central Hospital,Shanghai
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with cancer (confirmed by pathology or imaging) and experiencing cancer-related pain (NRS score >= 4); 2. Age >=18 years, with an expected survival period >= 3 months; 3. No chemotherapy or other analgesic treatments during the titration therapy period; 4. No prior treatment with oxycodone; 5. Voluntary participation in this study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Non-cancer-related pain; 2. Opioid tolerance; 3. Absolute neutrophil count = 1.5×ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >= 2.5×ULN, or AST >= 1.5×ULN and ALT >= 1.5×ULN in patients with liver metastases; 5. Severe renal insufficiency (eGFR < 30 mL/min); 6. Contraindications to oxycodone (e.g., severe respiratory depression, history of drug abuse, gastrointestinal obstruction); 7. Inability to cooperate with follow-up or data collection (e.g., cognitive impairment, language barrier); 8. Prior use of genetic testing to guide opioid therapy (to avoid confounding factors); 9. Pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Genotype;NRS Pain Score;Serum Pain Mediator Levels;Sleep Quality;Quality of Life;Anxiety Level; | — |
Countries
China
Contacts
Public ContactYuling Li
Putuo District Central Hospital, Shanghai
Outcome results
None listed